Abstract: The invention provides a system for pumping a fluid through a target unit, comprising a source of compressed gas, a gas circuit connected to said source of compressed gas and including gas flow control apparatus, a first connection and a second connection for connecting to, respectively, afferent and efferent ends of the target unit, a fluid flow circuit in fluid communication with said first and second connections, the fluid flow circuit including fluid control apparatus and a first and second fluid reservoir, wherein the gas flow control apparatus provides coordinated delivery and release of compressed gas to dynamically control fluid level in each of said first and second fluid reservoirs in order to provide, by way of operation of the fluid control apparatus in the fluid flow circuit, continuous fluid flow through the target unit in a single direction in accordance with a predetermined flow profile.

Abstract: Plasma polymerisation apparatus is disclosed including a reaction zone and at least one gas inlet for supplying at least one monomer in a gaseous form to the reaction zone, a first electrode and a second electrode spaced apart and configured to generate an electric field in the reaction zone to form plasma polymer nanoparticulate material from the at least one monomer, a plurality of collectors configured to collect plasma-polymer nanoparticulate material formed in the reaction zone, the plurality of collectors being located adjacent the second electrode, and a cooling device located adjacent the second electrode and configured to cool the plurality of collectors. Also disclosed is plasma polymerisation apparatus that includes a confinement grid extending between a first electrode and a second electrode of the apparatus.

Abstract: This application relates to nanoparticles, including nanoparticles derived from a plasma, and their use in the formation of conjugates. The nanoparticles can be stably conjugated to a wide variety of second species, forming conjugates which can be used, for example, in therapeutic, diagnostic and experimental methods.

Abstract: This application relates to nanoparticles, including nanoparticles derived from a plasma, and their use in the formation of conjugates. The nanoparticles can be stably conjugated to a wide variety of second species, forming conjugates which can be used, for example, in therapeutic, diagnostic and experimental methods.

Abstract: This application relates to nanoparticles, including nanoparticles derived from a plasma, and their use in the formation of conjugates. The nanoparticles can be stably conjugated to a wide variety of second species, forming conjugates which can be used, for example, in therapeutic, diagnostic and experimental methods.

Abstract: The present disclosure relates to the field of nanoparticles, conjugates thereof and their use in methods of treatment or prevention of vascular inflammation. The present disclosure also relates to methods of delivering an agent to a region of a blood vessel in a patient, comprising: a) conjugating the agent to a nanoparticle to produce a conjugate; and b) delivering the conjugate to the region of the blood vessel.

Abstract: Plasma polymerisation apparatus is disclosed including a reaction zone and at least one gas inlet for supplying at least one monomer in a gaseous form to the reaction zone, a first electrode and a second electrode spaced apart and configured to generate an electric field in the reaction zone to form plasma polymer nanoparticulate material from the at least one monomer, a plurality of collectors configured to collect plasma-polymer nanoparticulate material formed in the reaction zone, the plurality of collectors being located adjacent the second electrode, and a cooling device located adjacent the second electrode and configured to cool the plurality of collectors. Also disclosed is plasma polymerisation apparatus that includes a confinement grid extending between a first electrode and a second electrode of the apparatus.

Abstract: This application relates to nanoparticles, including nanoparticles derived from a plasma, and their use in the formation of conjugates. The nanoparticles can be stably conjugated to a wide variety of second species, forming conjugates which can be used, for example, in therapeutic, diagnostic and experimental methods.

Abstract: Biocompatible materials for use in vascular applications or for implantation have been engineered, combining human recombinant tropoelastin with other synthetic or natural biomaterials to form protoelastin. The materials can be in the form of elastin films on metal or polymer substrates, laminates of alternating polymer and elastin, blends of polymer and elastin, or elastin crosslinked with or tethered to polymer or metal. These are mechanically stable, elastic, strong and biocompatible (i.e., not thrombogenic and promoting adhesion of cells, especially human endothelial cells), not eliciting a foreign body response. Plasma polymerization of substrate is shown to enhance biocompatibility, especially when used to bind elastin or other protein to the substrate.

Abstract: Biocompatible materials for use in vascular applications or for implantation have been engineered, combining human recombinant tropoelastin with other synthetic or natural biomaterials to form protoelastin. The materials can be in the form of elastin films on metal or polymer substrates, laminates of alternating polymer and elastin, blends of polymer and elastin, or elastin crosslinked with or tethered to polymer or metal. These are mechanically stable, elastic, strong and biocompatible (i.e., not thrombogenic and promoting adhesion of cells, especially human endothelial cells), not eliciting a foreign body response. Plasma polymerization of substrate is shown to enhance biocompatibility, especially when used to bind elastin or other protein to the substrate.

Abstract: Biocompatible materials suitable for use in vascular applications have been engineered, combining human recombinant tropoelastin with other synthetic or natural biomaterials to form protoelastin. The materials can be in the form of elastin films on metal, bone, ceramic or polymer substrates, laminates of alternating polymer and elastin, blends of polymer and elastin, or elastin crosslinked with or tethered to polymer. The flexibility in engineering and design makes protoelastin biomaterials suited not only to the production of conduits but any number of other vascular applications that require blood contacting surfaces. Tropoelastin and the subsequently engineered biomaterial protoelastin provide the opportunity to satisfy a large unmet need for a biocompatible material adaptable enough to meet a range of diverse vascular uses. These are mechanically stable, elastic, strong and biocompatible (i.e., not thrombogenic and promoting adhesion of cells, especially human endothelial cells.